Heena Maithania
Heena Maithania has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Jasmin Monpara
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, Pennsylvania, 19104, USA
1 shared publication - Krishil Oswal
Department of Pharmacy Practice, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to Be) University, Pune, 411038, India
1 shared publication - Manoj Gundeti
Department of Pharmaceutics, College of Pharmacy University of Florida Gainesville FL USA
1 shared publication - Pooja Tiwary
Department of Pharmacy Practice, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to Be) University, Pune, 411038, India
1 shared publication - Raghunandhan Painoori
Regulatory Affairs, Odin Pharmaceuticals, Somerset, New Jersey, USA
1 shared publication - Rahul S. Kalhapure
Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa
1 shared publication
Latest Publications
- 26 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 117
Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective
Radiopharmaceuticals are biologically active molecules labeled with radionuclides that have advanced the possibility of the nuclear medicine. They support
- 26 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 117
Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective
Radiopharmaceuticals are biologically active molecules labeled with radionuclides that have advanced the possibility of the nuclear medicine. They support
- Open Access
- 28 January 2026
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 2 (1) , 2
A concise review on nanoscale carriers to target intracellular infections
The escalating global burden of infectious diseases necessitates the development of innovative strategies to curb their spread. Given that most pathogens reside within host cells, intracellular drug delivery has emerged as a promising avenue for formulation research and therapeutic intervention. Conventional drug delivery approaches, although extensive, pose challenges in achieving the effective concentration of the drug in the intracellular compartment. In contrast, lipid- and polymer-based nanoparticles offer distinct advantages, including enhanced cellular uptake, improved bioavailability, and superior therapeutic efficacy. This review provides a brief overview of the various lipid- and polymer-based nanocarriers and the recent advancements in their method of preparation for large-scale production. Furthermore, it explores key challenges associated with intracellular targeting and discusses future prospects for translating nanotechnology-driven carriers from laboratory research to clinical application.
- 28 January 2026
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 2 (1) , 2
Open AccessA concise review on nanoscale carriers to target intracellular infections
The escalating global burden of infectious diseases necessitates the development of innovative strategies to curb their spread. Given that most pathogens reside within host cells, intracellular drug delivery has emerged as a promising avenue for formulation research and therapeutic intervention. Conventional drug delivery approaches, although extensive, pose challenges in achieving the effective concentration of the drug in the intracellular compartment. In contrast, lipid- and polymer-based nanoparticles offer distinct advantages, including enhanced cellular uptake, improved bioavailability, and superior therapeutic efficacy. This review provides a brief overview of the various lipid- and polymer-based nanocarriers and the recent advancements in their method of preparation for large-scale production. Furthermore, it explores key challenges associated with intracellular targeting and discusses future prospects for translating nanotechnology-driven carriers from laboratory research to clinical application.